Last update 08 May 2025

AD-PluReceptor(MD Anderson Cancer Center)

Overview

Basic Info

Drug Type
Natural Killer Cell Therapies
Synonyms-
Target-
Action-
Mechanism
Natural killer cell replacements
Therapeutic Areas
Immune System DiseasesNervous System DiseasesSkin and Musculoskeletal Diseases+ [2]
Active Indication
Diffuse Cerebral Sclerosis of SchilderLupus NephritisScleroderma, Diffuse
Inactive Indication-
Originator Organization
The University of Texas MD Anderson Cancer CenterThe University of Texas MD Anderson Cancer Center
Active Organization
The University of Texas MD Anderson Cancer CenterThe University of Texas MD Anderson Cancer Center
Inactive Organization-
License Organization-
Drug Highest PhasePhase 1/2
First Approval Date-
Regulation-
Login to view timeline

Related

1
Clinical Trials associated with AD-PluReceptor(MD Anderson Cancer Center)
NCT06434363
/ RecruitingPhase 1/2IIT
Phase I/II Study of AD-PluReceptor Plus Tafasitamab-cxix and Lymphodepleting Chemotherapy in Patients With Autoimmune Disorders
100 Clinical Results associated with AD-PluReceptor(MD Anderson Cancer Center)
Login to view more data
100 Translational Medicine associated with AD-PluReceptor(MD Anderson Cancer Center)
Login to view more data
100 Patents (Medical) associated with AD-PluReceptor(MD Anderson Cancer Center)
Login to view more data
100 Deals associated with AD-PluReceptor(MD Anderson Cancer Center)
Login to view more data

R&D Status

10 top R&D records.
Login
to view more data
IndicationHighest PhaseCountry/LocationOrganizationDate
Diffuse Cerebral Sclerosis of SchilderPhase 2
United States
The University of Texas MD Anderson Cancer CenterThe University of Texas MD Anderson Cancer Center
31 Jul 2024
Lupus NephritisPhase 2
United States
The University of Texas MD Anderson Cancer CenterThe University of Texas MD Anderson Cancer Center
31 Jul 2024
Scleroderma, DiffusePhase 2
United States
The University of Texas MD Anderson Cancer CenterThe University of Texas MD Anderson Cancer Center
31 Jul 2024
Login to view more data

Clinical Result

Indication
Phase
Evaluation
View All Results
Study
Phase
PopulationAnalyzed EnrollmentGroupResultsEvaluationPublication Date

No Data

Login to view more data

Translational Medicine

Boost your research with our translational medicine data.
login
or
view full example data
Boost your research with our translational medicine data.

Deal

Boost your decision using our deal data.
login
or
view full example data
Boost your decision using our deal data.

Core Patent

Boost your research with our Core Patent data.
login
or
view full example data
Boost your research with our Core Patent data.

Clinical Trial

Identify the latest clinical trials across global registries.
login
or
view full example data
Identify the latest clinical trials across global registries.

Approval

Accelerate your research with the latest regulatory approval information.
login
or
view full example data
Accelerate your research with the latest regulatory approval information.

Regulation

Understand key drug designations in just a few clicks with Synapse.
login
or
view full example data
Understand key drug designations in just a few clicks with Synapse.
Chat with Hiro
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.
Bio
Bio Sequences Search & Analysis
Sign up for free
Chemical
Chemical Structures Search & Analysis
Sign up for free